135716-09-5

Basic information

• Product Name: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE
• Synonyms: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE;tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate(SALTDATA: FREE);Ethyl N-Boc-4-piperidineacetate;Ethyl 1-Boc-4-piperidine ...;Ethyl 1-Boc-4-piperidine acetate;1-[(tert-butoxy)carbonyl]-4-ethylpiperidine-2-carboxylate;tert-Butyl 4-(2-ethoxy-2-oxoethyl)piperidin-1-carboxylate;4-Piperidineacetic acid, 1-[(1,1-diMethylethoxy)carbonyl]-, ethyl ester
• CAS NO: 135716-09-5
• Molecular Formula: C₁₄H₂₅NO₄
• Molecular Weight: 271.35
• Mol File: 135716-09-5.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 339.2±15.0 °C(Predicted)
• Appearance: /
• Density: 1.048±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1?+-.0.40(Predicted)
• CAS DataBase Reference: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE(135716-09-5)
• EPA Substance Registry System: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE(135716-09-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 135716-09-5(Hazardous Substances Data)

Usage

General Description

N-BOC-4-ethyl piperidinecarboxylate is a chemical compound used as a building block in organic synthesis. It is a BOC-protected amino acid derivative, with the BOC (tert-butoxycarbonyl) group protecting the amino group. N-BOC-4-ETHYL PIPERIDINECARBOXYLATE is often used in the pharmaceutical industry for the synthesis of various drugs and drug candidates. Its unique structure and reactivity make it a valuable tool for the creation of complex organic molecules, and it is also used in research and development of new chemical and pharmaceutical products.

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 75-03-6 ethyl iodide 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 41979-39-9 4-piperidone hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 135716-12-0 (R)-(+)-2-(N-tert-butoxycarbonylpiperidin-4-yl)-2-(6-chloropyrazin-2-yl)ethanol 
• 64-17-5 ethanol 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 
• 1381841-47-9 C₂₀H₂₂ClN₃ 
• 1032825-55-0 tert-butyl 4-(1-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate 
• 1292321-48-2 C₂₂H₂₃F₂NO₄ 
• 1292321-47-1 C₂₉H₃₄F₂N₂O₅ 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 339525-21-2 1-(o-iodobenzoyl)-4-[4-(trimethylsilyl)but-3-ynyl]piperidine 
• 339525-17-6 1-(o-iodobenzoyl)-4-[3-(trimethylsilyl)prop-2-ynyl]piperidine 
• 301185-40-0 1-(t-butoxycarbonyl)-4-(3,3-dibromoprop-2-en-1-yl)piperidine 

Relevant articles and documents

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease

A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer's disease. Starting from a reported 5-HT4R antagonist, a systematic structure-activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical-pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION

Provided are a compound represented by formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic mixture, or prodrug thereof, and a preparation method thereof, and an application for preparing a pharmaceutical product for treating a disease related to obstructed airways, wherein each substituent in the compound represented by formula (I) is as described in the specification.